Active Share (vs S&P 500): 97.6%
· vs QQQ: 97.6%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-13.5%
· vs SPY
-15.6%
· Prev Value $4.93B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-4.2%
· vs SPY
-6.4%
· Latest Value $4.21B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, Siren, L.L.C. disclosed 109 equity positions with a combined reported value of $4.21B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were SRRK ($453.00M), KYMR ($311.32M), ERAS ($193.48M). By sector, the heaviest allocations are Health Care 94.0%, Technology 4.2%. Versus the prior quarter, allocation shifted toward Health Care (+1.9pp) and away from Financials (-0.7pp), Other (-0.7pp).
Versus the prior quarter, Siren, L.L.C. opened 15 new positions, trimmed 36 and fully exited 22, a turnover rate of 55.7% of positions. The portfolio's overlap with the prior quarter was 72% of names.
The largest new positions opened in Q3 2026 were VNDA ($38.40M), ASND ($29.62M), DARE ($15.20M).
Of the 22 positions fully exited versus the prior quarter, the largest were DFTX ($66.77M), CRNX ($53.17M), COF ($34.43M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest Siren, L.L.C. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Siren, L.L.C. files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 116 positions worth $4.93B in total. HoldingsHub carries 8 quarters of its filings (Q3 2024–Q2 2026).
Portfolio Structure
116 positions · $4.93B reported value (Q2 2026)
Top 10 holdings = 44.8% of reported value
Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 10.7%
Average position size: $42.48M
Sector Tilt
Health Care 92.0%
Information Technology 4.5%
Consumer Discretionary 1.2%
(classified holdings cover 99% of value)
Quarterly Activity
Q2 2026: 25 new, 32 added, 21 reduced, 9 exited
38 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund is actively reducing exposure to most top-10 holdings (7/10) while selectively adding to a few, suggesting a cautious stance on current biotech/healthcare positions but targeted bets on specific catalysts.
2. Key moves:
- Added: ERAS (+15.8% shares), TNGX (+9.8%), ARWR (+33.5%)
- Reduced: SRRK (-2.1%), KYMR (-5.1%), RVMD (-5.6%), MANE (-20.0%), EWTX (-11.9%), RYTM (-4.4%)
- Hold: ONC (no change)
3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with high risk appetite (small-cap biotech/therapeutics).
4. Per-holding one-liner:
- SRRK: Scholar Rock (biopharma, unverified)
- KYMR: Kymera Therapeutics (drug discovery, unverified)
- ERAS: Erasca (cancer therapeutics, unverified)
- RVMD: Revolution Medicines (cancer R&D, unverified)
- ONC: BEONE MEDICINES (oncology, unverified)
- TNGX: Tango Therapeutics (cancer genomics, unverified)
- MANE: Veradermics (dermatology, unverified)
- ARWR: Arrowhead Pharmaceuticals (gene therapy, unverified)
- EWTX: Edgewise Therapeutics (muscle disorders, unverified)
- RYTM: Rhythm Pharmaceuticals (obesity/rare disease, unverified)
5. Style summary: Cautiously selective biotech fund trimming broadly while doubling down on high-conviction catalysts.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-13 04:12
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2025-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
This portfolio is broadly diversified (Top-10 = 47.2% of reported value), so a
Top-10 proxy cannot represent the whole fund — only the full-holdings reconstruction is shown.
Why there is no forecast NAV
Not published because:
Top-10 covers < 85% of reported value · Holdings-forecast backtest F1 < 0.80 · Top-10 quarterly turnover > 20%
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-11.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-11, and will update as prices arrive.
Portfolio return-2.60%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return+8.55%vs benchmark
Barra annualised vol40.2%Model estimate
Realised vol42.9%Annualised in window
Weighted beta1.18Raw exposure
Factor / specific risk55% / 45%Share of variance
Top-10 concentration90.3%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-2.60%
Disclosed long book
QQQ synthetic benchmark
-11.15%
Liquidity-weighted constituents
Model universe, equal weight
+2.07%
Opportunity-cost reference
Excess return
+8.55%
Portfolio − benchmark
Arithmetic return sum
-1.58%
Difference vs compounded is the cross term
Weighted raw beta
1.18
Weighted holding betas
Realised volatility (annualised)
42.91%
Daily returns in window
Barra model volatility (annualised)
40.24%
Factor + specific
Factor share of variance
55.3%
Barra factors
Specific share of variance
44.7%
Stock residuals
Reported value
$1.31B
13F long US equity
2. Return attribution
The -1.58% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
-1.26%
-79.9%
Momentum & Growth
3
-4.85%
-307.9%
Volatility & Tail Risk
7
-0.85%
-54.3%
Industry
12
+8.18%
519.1%
Specific
1
-2.79%
-177.0%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Health Care
Industry
+0.88
+9.47%
+8.34%
529.5%
Residual Volatility
Style
+2.03
+2.15%
+4.36%
277.1%
Size
Style
-1.17
-1.93%
+2.25%
142.9%
Beta
Style
+0.34
+4.92%
+1.67%
106.0%
Amihud Illiquidity
Style
+2.17
+0.30%
+0.65%
41.4%
Short-term Reversal
Style
+0.55
+1.12%
+0.61%
38.7%
Leverage (Downside Vol)
Style
-0.06
-3.05%
+0.19%
11.8%
Non-linear Size
Style
+2.41
+0.07%
+0.17%
10.5%
Max Drawdown
Style
+0.06
-1.01%
-0.06%
-3.6%
Liquidity
Style
+0.80
-0.20%
-0.16%
-10.3%
Information Technology
Industry
+0.11
-2.11%
-0.22%
-14.2%
Turnover
Style
+0.09
-4.35%
-0.41%
-25.9%
Growth
Style
-0.65
+1.50%
-0.97%
-61.8%
Skewness
Style
+0.21
-4.77%
-1.02%
-64.8%
Kurtosis
Style
-0.32
+6.17%
-1.94%
-123.4%
Specific
Specific
—
—
-2.79%
-177.0%
Mid Cap
Style
+1.96
-1.92%
-3.76%
-238.6%
Historical Volatility
Style
+0.41
-9.82%
-4.05%
-257.3%
Momentum
Style
+1.35
-3.32%
-4.49%
-284.8%
3. Risk attribution
Annualised volatility is 40.24%; factor risk explains 55.3% of variance and specific risk 44.7%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
44.7%
+17.97%
18.0%
Health Care
Industry
+0.88
13.8%
+5.55%
5.5%
Residual Volatility
Style
+2.03
9.2%
+3.70%
3.7%
Mid Cap
Style
+1.96
8.6%
+3.44%
3.4%
Momentum
Style
+1.35
6.2%
+2.50%
2.5%
Size
Style
-1.17
4.3%
+1.75%
1.8%
Beta
Style
+0.34
3.8%
+1.55%
1.6%
Amihud Illiquidity
Style
+2.17
2.6%
+1.04%
1.0%
Liquidity
Style
+0.80
2.3%
+0.93%
0.9%
Non-linear Size
Style
+2.41
1.9%
+0.78%
0.8%
Historical Volatility
Style
+0.41
1.5%
+0.62%
0.6%
Information Technology
Industry
+0.11
1.5%
+0.61%
0.6%
Short-term Reversal
Style
+0.55
0.6%
+0.23%
0.2%
Skewness
Style
+0.21
-0.3%
-0.12%
-0.1%
Growth
Style
-0.65
-1.2%
-0.48%
-0.5%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.17
+2.10
-3.27
Non-linear Size
+2.41
+1.68
+0.73
Mid Cap
+1.96
+0.13
+1.83
Beta
+0.34
+1.29
-0.95
Momentum
+1.35
+0.72
+0.64
Short-term Reversal
+0.55
-0.64
+1.19
Residual Volatility
+2.03
-0.40
+2.43
Historical Volatility
+0.41
+0.86
-0.45
Liquidity
+0.80
+0.11
+0.69
Amihud Illiquidity
+2.17
+1.16
+1.02
Turnover
+0.09
+0.21
-0.11
Growth
-0.65
+0.58
-1.23
Leverage (Downside Vol)
-0.06
+0.14
-0.20
Skewness
+0.21
+0.24
-0.02
Kurtosis
-0.32
+0.21
-0.53
Max Drawdown
+0.06
-0.08
+0.14
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
10.6%
73.6%
-14.94%
-16.67%
+3.95%
+1.27%
-1.09%
+10.68%
Communication Services
0.0%
2.6%
+0.00%
-12.15%
+0.05%
+0.32%
-0.32%
+0.32%
Utilities
0.0%
0.8%
+0.00%
+10.14%
-0.16%
-0.08%
+0.08%
-0.08%
Consumer Staples
0.0%
0.8%
+25.98%
+15.33%
-0.21%
+0.09%
-0.09%
-0.12%
Financials
0.6%
0.0%
-28.83%
+0.00%
+0.06%
-0.00%
-0.17%
-0.17%
Consumer Discretionary
0.5%
8.8%
+7.02%
+5.93%
-1.36%
+0.10%
-0.09%
-0.49%
Industrials
0.0%
11.1%
+0.00%
+7.87%
-2.03%
-0.87%
+0.87%
-0.87%
Health Care
88.1%
1.7%
-1.75%
+9.50%
+17.19%
-0.19%
-9.72%
-1.71%
Total
+17.41%
+0.59%
-10.48%
+7.52%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
SRRK
Scholar Rock Holding Corporation
Health Care
34.68%
-3.56%
-1.23%
Reduce
RVMD
REVOLUTION MEDICINES INC
Health Care
13.36%
-11.96%
-1.60%
Reduce
ONC
BEONE MEDICINES LTD
Health Care
13.03%
+14.77%
+1.92%
Hold
TNGX
Tango Therapeutics, Inc.
Health Care
12.96%
+3.13%
+0.40%
Add
RLAY
Relay Therapeutics, Inc.
Health Care
4.51%
+9.25%
+0.42%
Reduce
TSHA
Taysha Gene Therapies, Inc.
Health Care
3.67%
-12.12%
-0.45%
Hold
DNLI
Denali Therapeutics Inc.
Health Care
2.21%
-4.55%
-0.10%
Hold
GOOGL
ALPHABET INC
Information Technology
2.11%
-14.71%
-0.31%
Reduce
GPCR
Structure Therapeutics Inc.
Health Care
2.09%
-33.00%
-0.69%
Hold
NVDA
NVIDIA CORPORATION
Information Technology
1.70%
-23.93%
-0.41%
Add
TSM
TAIWAN SEMICONDUCTOR MANUFAC
Information Technology
1.57%
-9.39%
-0.15%
Add
MSFT
MICROSOFT CORP
Information Technology
0.94%
+1.60%
+0.01%
Hold
NOW
SERVICENOW INC
Information Technology
0.92%
-23.32%
-0.21%
Reduce
NBIS
NEBIUS GROUP N.V.
Information Technology
0.86%
-34.42%
-0.29%
Reduce
GENB
Generate Biomedicines Inc
Health Care
0.85%
-10.19%
-0.09%
Hold
AVGO
BROADCOM INC
Information Technology
0.79%
-1.70%
-0.01%
Add
FROG
JFrog Ltd.
Information Technology
0.49%
+12.85%
+0.06%
Reduce
AMZN
AMAZON COM INC
Consumer Discretionary
0.41%
+6.83%
+0.03%
Reduce
CRWD
CROWDSTRIKE HLDGS INC
Information Technology
0.40%
-13.48%
-0.06%
Add
DDOG
DATADOG INC
Information Technology
0.38%
-32.67%
-0.12%
Reduce
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
ONC
Health Care
13.03%
+14.77%
+1.92%
2
RLAY
Health Care
4.51%
+9.25%
+0.42%
3
TNGX
Health Care
12.96%
+3.13%
+0.40%
4
FROG
Information Technology
0.49%
+12.85%
+0.06%
5
AMZN
Consumer Discretionary
0.41%
+6.83%
+0.03%
6
MSFT
Information Technology
0.94%
+1.60%
+0.01%
7
ZTS
Health Care
0.07%
+18.24%
+0.01%
8
PRMB
Consumer Staples
0.04%
+25.98%
+0.01%
9
NVDA
Information Technology
1.70%
-23.93%
-0.41%
10
TSHA
Health Care
3.67%
-12.12%
-0.45%
11
GPCR
Health Care
2.09%
-33.00%
-0.69%
12
SRRK
Health Care
34.68%
-3.56%
-1.23%
13
RVMD
Health Care
13.36%
-11.96%
-1.60%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-11 (30 trading days), the reported portfolio returned -2.60%, versus -11.15% for the QQQ synthetic benchmark — an excess of +8.55%.
Return attribution: the largest positive style/industry contributions came from Health Care +8.34%, Residual Volatility +4.36%, Size +2.25%; the largest drags came from Momentum -4.49%, Historical Volatility -4.05%, Mid Cap -3.76%. Specific (stock-level) return contributed -2.79%.
Risk attribution: Barra model volatility is 40.24% annualised; factor risk explains 55% of variance and specific risk 45%. The largest factor risk sources are Health Care 13.8%, Residual Volatility 9.2%, Mid Cap 8.6%.
Style tilt: size -1.17, momentum +1.35, volatility +0.41, liquidity +0.80; the weighted raw beta is 1.18. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+86.4 pp), the largest underweight is Information Technology (-63.0 pp). Allocation contributed +17.41%, selection +0.59% and interaction -10.48%.
Concentration: the top-10 positions are 90.3% of the attributed portfolio and the model covers 97.9% of its value with full style exposures; the remainder is mapped to its sector only. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Siren, L.L.C. buy in 2026-Q3?
In its 2026-Q3 13F filing, Siren, L.L.C. reported 109 equity positions worth $4.21B in aggregate; its largest disclosed positions were SRRK ($453.00M), KYMR ($311.32M), ERAS ($193.48M).
How large is Siren, L.L.C.'s portfolio?
Siren, L.L.C. reported $4.21B of long equity holdings across 109 positions as of 2026-Q3. Top-10 holdings account for 47.5% of reported value.
What is Siren, L.L.C.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/siren/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>